Tiziana Life Sciences Ltd (TLSA) - Net Assets
Based on the latest financial reports, Tiziana Life Sciences Ltd (TLSA) has net assets worth $9.20 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.60 Million) and total liabilities ($7.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TLSA financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.20 Million |
| % of Total Assets | 55.43% |
| Annual Growth Rate | 2.17% |
| 5-Year Change | -93.69% |
| 10-Year Change | -53.72% |
| Growth Volatility | 251.47 |
Tiziana Life Sciences Ltd - Net Assets Trend (1998–2024)
This chart illustrates how Tiziana Life Sciences Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Tiziana Life Sciences Ltd assets under control for the complete picture of this company's asset base.
Annual Net Assets for Tiziana Life Sciences Ltd (1998–2024)
The table below shows the annual net assets of Tiziana Life Sciences Ltd from 1998 to 2024. For live valuation and market cap data, see TLSA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.94 Million | -28.90% |
| 2023-12-31 | $5.54 Million | -71.71% |
| 2022-12-31 | $19.57 Million | -52.59% |
| 2021-12-31 | $41.28 Million | -33.83% |
| 2020-12-31 | $62.39 Million | +1592.49% |
| 2019-12-31 | $-4.18 Million | -1121.97% |
| 2018-12-31 | $409.01K | +124.30% |
| 2017-12-31 | $-1.68 Million | -150.78% |
| 2016-12-31 | $3.31 Million | -61.03% |
| 2015-12-31 | $8.50 Million | +378.56% |
| 2014-12-31 | $1.78 Million | +1317.12% |
| 2013-12-31 | $-146.00K | -265.00% |
| 2012-12-31 | $-40.00K | -107.62% |
| 2011-12-31 | $525.00K | -13.08% |
| 2010-12-31 | $604.00K | -50.21% |
| 2009-12-31 | $1.21 Million | -9.48% |
| 2008-12-31 | $1.34 Million | -45.08% |
| 2007-12-31 | $2.44 Million | +0.49% |
| 2006-12-31 | $2.43 Million | -14.05% |
| 2005-12-31 | $2.83 Million | -20.27% |
| 2004-12-31 | $3.54 Million | +17.05% |
| 2003-12-31 | $3.03 Million | +37.28% |
| 2002-12-31 | $2.21 Million | -25.56% |
| 2001-12-31 | $2.96 Million | -26.08% |
| 2000-12-31 | $4.01 Million | +101.97% |
| 1999-12-31 | $1.98 Million | -11.94% |
| 1998-12-31 | $2.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tiziana Life Sciences Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14455900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $111.00K | 2.82% |
| Other Comprehensive Income | $116.99 Million | 2972.31% |
| Other Components | $31.67 Million | 804.52% |
| Total Equity | $3.94 Million | 100.00% |
Tiziana Life Sciences Ltd Competitors by Market Cap
The table below lists competitors of Tiziana Life Sciences Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FutureFuel Corp
NYSE:FF
|
$161.63 Million |
|
SK D&D Co Ltd
KO:210980
|
$161.65 Million |
|
Haesung Industrial Co. Ltd
KQ:034810
|
$161.66 Million |
|
Jean Co Ltd
TW:2442
|
$161.67 Million |
|
Financiera Independencia S.A.B. de C.V. SOFOM E.N.R
MX:FINDEP
|
$161.60 Million |
|
Englewood Lab Inc
KQ:950140
|
$161.57 Million |
|
Mnc Investama Tbk
JK:BHIT
|
$161.54 Million |
|
INFOM
KLSE:0265
|
$161.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tiziana Life Sciences Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,536,000 to 3,936,000, a change of -1,600,000 (-28.9%).
- Net loss of 11,863,000 reduced equity.
- New share issuances of 4,571,000 increased equity.
- Other comprehensive income decreased equity by 71,000.
- Other factors increased equity by 5,763,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.86 Million | -301.4% |
| Share Issuances | $4.57 Million | +116.13% |
| Other Comprehensive Income | $-71.00K | -1.8% |
| Other Changes | $5.76 Million | +146.42% |
| Total Change | $- | -28.90% |
Book Value vs Market Value Analysis
This analysis compares Tiziana Life Sciences Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 18.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 18.16x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $2627.04 | $1.34 | x |
| 1999-12-31 | $2391.57 | $1.34 | x |
| 2000-12-31 | $4892.55 | $1.34 | x |
| 2001-12-31 | $2829.04 | $1.34 | x |
| 2002-12-31 | $957.86 | $1.34 | x |
| 2003-12-31 | $647.07 | $1.34 | x |
| 2004-12-31 | $640.34 | $1.34 | x |
| 2005-12-31 | $346.50 | $1.34 | x |
| 2006-12-31 | $191.35 | $1.34 | x |
| 2007-12-31 | $138.10 | $1.34 | x |
| 2008-12-31 | $40.96 | $1.34 | x |
| 2009-12-31 | $11.71 | $1.34 | x |
| 2010-12-31 | $1.72 | $1.34 | x |
| 2011-12-31 | $0.80 | $1.34 | x |
| 2012-12-31 | $-0.04 | $1.34 | x |
| 2013-12-31 | $-0.01 | $1.34 | x |
| 2014-12-31 | $0.31 | $1.34 | x |
| 2015-12-31 | $0.18 | $1.34 | x |
| 2016-12-31 | $0.06 | $1.34 | x |
| 2017-12-31 | $-0.03 | $1.34 | x |
| 2018-12-31 | $0.01 | $1.34 | x |
| 2019-12-31 | $-0.06 | $1.34 | x |
| 2020-12-31 | $0.94 | $1.34 | x |
| 2021-12-31 | $0.84 | $1.34 | x |
| 2022-12-31 | $0.39 | $1.34 | x |
| 2023-12-31 | $0.11 | $1.34 | x |
| 2024-12-31 | $0.07 | $1.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tiziana Life Sciences Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -301.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.87x
- Recent ROE (-301.40%) is below the historical average (-175.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -12.07% | 0.00% | 0.00x | 1.19x | $-497.40K |
| 1999 | -27.91% | 0.00% | 0.00x | 1.18x | $-752.50K |
| 2000 | -56.60% | 0.00% | 0.00x | 1.12x | $-2.67 Million |
| 2001 | -78.49% | 0.00% | 0.00x | 1.12x | $-2.62 Million |
| 2002 | -104.58% | 0.00% | 0.00x | 1.16x | $-2.53 Million |
| 2003 | -64.82% | 0.00% | 0.00x | 1.09x | $-2.26 Million |
| 2004 | -39.18% | -1402.02% | 0.02x | 1.17x | $-1.74 Million |
| 2005 | -75.79% | -1845.69% | 0.03x | 1.22x | $-2.42 Million |
| 2006 | -89.62% | -537.28% | 0.13x | 1.30x | $-2.42 Million |
| 2007 | -99.06% | -3776.56% | 0.02x | 1.19x | $-2.66 Million |
| 2008 | -106.64% | -1553.26% | 0.05x | 1.48x | $-1.56 Million |
| 2009 | -60.18% | -1303.57% | 0.03x | 1.43x | $-851.30K |
| 2010 | -774.51% | 0.00% | 0.00x | 1.69x | $-4.74 Million |
| 2011 | -230.08% | 0.00% | -0.20x | 1.19x | $-1.26 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-844.00K |
| 2013 | 0.00% | -9333.33% | 0.02x | 0.00x | $-265.40K |
| 2014 | -197.52% | 0.00% | 0.00x | 1.38x | $-3.69 Million |
| 2015 | -150.38% | 0.00% | 0.00x | 1.09x | $-13.64 Million |
| 2016 | -217.50% | 0.00% | 0.00x | 1.52x | $-7.54 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.60 Million |
| 2018 | -1540.08% | 0.00% | 0.00x | 13.33x | $-6.34 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.89 Million |
| 2020 | -57.17% | 0.00% | 0.00x | 1.55x | $-30.70 Million |
| 2021 | -56.73% | 0.00% | 0.00x | 1.18x | $-27.55 Million |
| 2022 | -78.67% | 0.00% | 0.00x | 1.35x | $-17.35 Million |
| 2023 | -319.56% | 0.00% | 0.00x | 2.20x | $-18.24 Million |
| 2024 | -301.40% | 0.00% | 0.00x | 2.87x | $-12.26 Million |
Industry Comparison
This section compares Tiziana Life Sciences Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tiziana Life Sciences Ltd (TLSA) | $9.20 Million | -12.07% | 0.80x | $161.60 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more